1
|
Gavrish E, Sit CS, Cao S, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A, Hughes D, Bissell A, Torrey H, Akopian T, Mueller A, Epstein S, Goldberg A, Clardy J, Lewis K. Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. ACTA ACUST UNITED AC 2014; 21:509-518. [PMID: 24684906 DOI: 10.1016/j.chembiol.2014.01.014] [Citation(s) in RCA: 258] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Revised: 01/27/2014] [Accepted: 01/31/2014] [Indexed: 10/25/2022]
Abstract
Languishing antibiotic discovery and flourishing antibiotic resistance have prompted the development of alternative untapped sources for antibiotic discovery, including previously uncultured bacteria. Here, we screen extracts from uncultured species against Mycobacterium tuberculosis and identify lassomycin, an antibiotic that exhibits potent bactericidal activity against both growing and dormant mycobacteria, including drug-resistant forms of M. tuberculosis, but little activity against other bacteria or mammalian cells. Lassomycin is a highly basic, ribosomally encoded cyclic peptide with an unusual structural fold that only partially resembles that of other lasso peptides. We show that lassomycin binds to a highly acidic region of the ClpC1 ATPase complex and markedly stimulates its ATPase activity without stimulating ClpP1P2-catalyzed protein breakdown, which is essential for viability of mycobacteria. This mechanism, uncoupling ATPase from proteolytic activity, accounts for the bactericidal activity of lassomycin.
Collapse
Affiliation(s)
- Ekaterina Gavrish
- Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA
| | - Clarissa S Sit
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | - Shugeng Cao
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | - Olga Kandror
- Goldberg Laboratory, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Amy Spoering
- NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA
| | - Aaron Peoples
- NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA
| | - Losee Ling
- NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA
| | | | - Dallas Hughes
- NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA
| | - Anthony Bissell
- Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA
| | - Heather Torrey
- Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA
| | - Tatos Akopian
- Goldberg Laboratory, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Andreas Mueller
- Goldberg Laboratory, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Slava Epstein
- Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA
| | - Alfred Goldberg
- Goldberg Laboratory, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Jon Clardy
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
| | - Kim Lewis
- Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA.
| |
Collapse
|